Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats


Autoria(s): Bomfim, Gisele Facholi; Eichler, Rosangela Aparecida dos Santos; Oliveira, Maria Aparecida; Vitorino, Fernanda Regina Casagrande Giachini; Akamine, Eliana Hiromi; Passaglia, Rita de Cassia Aleixo Tostes; Fortes, Zuleica Bruno; Webb, R. Clinton; Carvalho, Maria Helena Catelli de
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

31/10/2013

31/10/2013

2012

Resumo

Activation of TLRs (Toll-like receptors) induces gene expression of proteins involved in the immune system response. TLR4 has been implicated in the development and progression of CVDs (cardiovascular diseases). Innate and adaptive immunity contribute to hypertension-associated end-organ damage, although the mechanism by which this occurs remains unclear. In the present study, we hypothesize that inhibition of TLR4 decreases BP (blood pressure) and improves vascular contractility in resistance arteries from SHR (spontaneously hypertensive rats). TLR4 protein expression in mesenteric resistance arteries was higher in 15-week-old SHR than in age-matched Wistar controls or in 5-week-old SHR. To decrease the activation of TLR4, 15-week-old SHR and Wistar rats were treated with anti-TLR4 (anti-TLR4 antibody) or non-specific IgG control antibody for 15 days (1 mu g per day, intraperitoneal). Treatment with anti-TLR4 decreased MAP (mean arterial pressure) as well as TLR4 protein expression in mesenteric resistance arteries and IL-6 (interleukin 6) serum levels from SHR when compared with SHR treated with IgG. No changes in these parameters were found in treated Wistar control rats. Mesenteric resistance arteries from anti-TLR4-treated SHR exhibited decreased maximal contractile response to NA (noradrenaline) compared with IgG-treated SHR. Inhibition of COX (cyclo-oxygenase)-1 and COX-2, enzymes related to inflammatory pathways, decreased NA responses only in mesenteric resistance arteries of SHR treated with IgG. COX-2 expression and TXA(2) (thromboxane A(2)) release were decreased in SHR treated with anti-TLR4 compared with IgG-treated SHR. Our results suggest that TLR4 activation contributes to increased BP, low-grade inflammation and plays a role in the augmented vascular contractility displayed by SHR.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil

National Institutes of Health

National Institutes of Health [NIH HL071138, DK083695]

Identificador

CLINICAL SCIENCE, LONDON, v. 122, n. 41619, supl. 1, Part 3, pp. 535-543, JUN, 2012

0143-5221

http://www.producao.usp.br/handle/BDPI/37018

10.1042/CS20110523

http://dx.doi.org/10.1042/CS20110523

Idioma(s)

eng

Publicador

PORTLAND PRESS LTD

LONDON

Relação

CLINICAL SCIENCE

Direitos

restrictedAccess

Copyright PORTLAND PRESS LTD

Palavras-Chave #CYCLO-OXYGENASE #HYPERTENSION #INFLAMMATION #MESENTERIC RESISTANCE ARTERY #TOLL-LIKE RECEPTOR 4 (TLR4) #SMOOTH-MUSCLE-CELLS #C-REACTIVE PROTEIN #INFLAMMATORY CYTOKINES #CARDIOVASCULAR-DISEASE #SIGNALING PATHWAY #FATTY-ACIDS #KAPPA-B #INTERLEUKIN-6 #TLR4 #ACTIVATION #MEDICINE, RESEARCH & EXPERIMENTAL
Tipo

article

original article

publishedVersion